USC Price School of Public Policy

Goldman proposes assessing new drugs on value brought to society

June 8, 2017

STAT published commentary by Dana Goldman and Anupam Jena of the USC Schaeffer Center on the difficulties associated with implementing fair, value-based drug pricing. One of the primary mechanisms Goldman and Jena recommend is increasing transparency in the assessment of a drug’s value. “If a drug creates value for society, we should figure out ways to finance its cost,” the authors also wrote.

Value-based drug pricing makes sense, but is difficult to pull off